| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2875882 | The Annals of Thoracic Surgery | 2012 | 8 Pages |
Abstract
Patients with LMCA disease who were treated with OPCAB showed better 5-year freedom from MACCEs in a real-world practice and in a patient matching cohort compared with the drug-eluting stenting group. TVR was the main factor that made the difference. The benefit of OPCAB was more prominent in distal LMCA lesions and in LMCA lesions with multivessel involvement.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gijong MD, PhD, Young-Nam MD, PhD, Soonchang MD, Suk-Won MD, PhD, Kyung-Jong MD, PhD,